片仔癀(600436.SH):阿哌沙班片獲批上市
格隆匯11月15日丨片仔癀(600436.SH)公佈,近日,公司收到國家藥品監督管理局核准簽發的《藥品註冊證書》,藥品名稱為阿哌沙班片。
阿哌沙班是一種強效、口服有效的可逆、直接、高選擇性的Xa因子活性位點抑制劑,其安全性高,耐受性好,受到廣大醫生和患者的認可。
阿哌沙班片是由百時美施貴寶和輝瑞聯合研發的新型口服抗凝藥,主要用於髖關節或膝關節擇期置換術的成年患者,預防靜脈血栓栓塞事件(VTE),2012年在美國首次獲批上市,2013年在我國獲批進口,已被列入2020版國家醫保目錄乙類品種。
目前國內阿哌沙班片的生產企業主要有正大天晴藥業集團股份有限公司、齊魯製藥(海南)有限公司、四川科倫藥業股份有限公司等。根據米內網公開數據,2018年至2020年中國(城市公立,城市社區,縣級公立,鄉鎮衞生)樣本醫院年度銷售趨勢顯示,阿哌沙班片的銷售額依次為3175萬元、5394萬元、11047萬元。
截至公吿日,該藥品項目的研發投入(未經審計)累計約1700萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.